Gain Therapeutics Inc (GANX) Stock Price, Quote & News

Company Profile

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 500 1556

Website: gaintherapeutics.com

Address:

4800 Montgomery Lane, Suite 220, Bethesda, United States

microcapspeculator Mar. 21 at 7:04 PM

$GANX Nice post by Roche scientist. Novel biomarkers are going to be key to showing success in future of slowing Parkinson’s.

2 · Reply

Mateuszrozek Mar. 21 at 9:17 AM

$RYTM $GANX +100% on monday? 😏😏😏

1 · Reply

rustinpeace Mar. 21 at 2:50 AM

$GANX bring on the phase 2. between may and july is the target start pending FDA . and 111 patients in the USA. start that data rolling.

3 · Reply

SirDuncan Mar. 21 at 2:43 AM

$GANX allow me to once and for all settle this misspeak from Gene. What he really meant to say was that we are a SELL at $20. So cmon, let’s sell for $20. A billion is a nice, crisp amount.

1 · Reply

Cmoneyyyyy11 Mar. 21 at 1:26 AM

$GANX cmon Gene we are a buy @ $20

1 · Reply

AtomBull27 Mar. 20 at 10:10 PM

$GANX back in 2022/23 why did it run to $5?

1 · Reply

zampy Mar. 20 at 8:58 PM

$GANX Pinball Wizard shorting again at $1.89!!! The illustrious Tom Getty...Contra indicator!! EZZZZZZ $$$$$$$$$ HERE

0 · Reply

zampy Mar. 20 at 8:17 PM

$GANX 2s next week....I think $2.15+....Keep the faith..I like the volume 745k .....

2 · Reply

Dave2468999077844 Mar. 20 at 8:17 PM

$GANX strong all day. smart money is accumulating while dumb retail sells it to them at fire sale prices. just like immu back in the day. this companies biggest issue is its shareholder base. its changin though.

0 · Reply

graphicswizard Mar. 20 at 8:15 PM

$GANX everyone knows that during these tumultuous times, invest in a safe asset like Gain Therapeutics stock 😝 Have a nice weekend everyone

0 · Reply

Gain Therapeutics to Present at the 38th Annual ROTH Conference

Mar 18, 2026, 8:15 AM EDT - 3 days ago

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

Mar 12, 2026, 7:00 AM EDT - 9 days ago

Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update

Feb 19, 2026, 7:00 AM EST - 4 weeks ago

Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Jan 7, 2026, 7:00 AM EST - 2 months ago

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Jan 6, 2026, 7:00 AM EST - 2 months ago

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

Dec 18, 2025, 4:05 PM EST - 3 months ago

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease

Dec 18, 2025, 7:00 AM EST - 3 months ago

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease

Nov 20, 2025, 7:00 AM EST - 4 months ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

Nov 12, 2025, 7:00 AM EST - 4 months ago

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

Nov 7, 2025, 4:16 AM EST - 4 months ago

Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients

Oct 30, 2025, 7:00 AM EDT - 5 months ago

Gain Therapeutics to Present at Neuroscience 2025

Oct 16, 2025, 7:00 AM EDT - 5 months ago

Gain Therapeutics to Attend the 2025 Maxim Growth Summit

Oct 6, 2025, 8:15 AM EDT - 5 months ago

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®

Sep 23, 2025, 7:40 AM EDT - 6 months ago

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

Sep 18, 2025, 7:41 AM EDT - 6 months ago

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease

Sep 4, 2025, 8:00 AM EDT - 7 months ago

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

Aug 12, 2025, 7:00 AM EDT - 7 months ago

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

Jul 24, 2025, 8:53 AM EDT - 8 months ago

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

Jul 16, 2025, 9:03 AM EDT - 8 months ago

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

Jul 15, 2025, 4:36 PM EDT - 8 months ago

Gain Therapeutics Announces Proposed Public Offering

Jun 30, 2025, 4:05 PM EDT - 9 months ago

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation

Jun 10, 2025, 8:00 AM EDT - 10 months ago

Gain Therapeutics to Participate in Upcoming Investor Conferences

May 29, 2025, 8:45 AM EDT - 10 months ago

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

May 14, 2025, 7:30 AM EDT - 11 months ago

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

May 12, 2025, 7:30 AM EDT - 11 months ago

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

May 1, 2025, 7:30 AM EDT - 11 months ago

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

Apr 30, 2025, 7:45 AM EDT - 11 months ago

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Gain Therapeutics Announces Poster Presentation at AD/PD 2025

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

Mar 14, 2025, 7:45 AM EDT - 1 year ago

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease

Mar 6, 2025, 7:55 AM EST - 1 year ago

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

Feb 6, 2025, 8:45 AM EST - 1 year ago

Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

Feb 5, 2025, 8:30 AM EST - 1 year ago

Gain Therapeutics To Participate in Upcoming Investor Conferences

Dec 31, 2024, 12:23 PM EST - 1 year ago

Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results

Dec 23, 2024, 7:30 AM EST - 1 year ago

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease

Dec 11, 2024, 8:30 AM EST - 1 year ago

Gain Therapeutics To Present At Biotech Showcase 2025

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

Oct 3, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics to Participate at Upcoming Investor Conferences

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Sep 26, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

Aug 29, 2024, 7:30 AM EDT - 1 year ago

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease

Jul 1, 2024, 10:13 AM EDT - 1 year ago

Gain Therapeutics, Inc. (GANX) Special Call Transcript

Jun 28, 2024, 4:39 PM EDT - 1 year ago

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

Jun 27, 2024, 4:08 PM EDT - 1 year ago

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Jun 27, 2024, 8:35 AM EDT - 1 year ago

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson's disease

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

microcapspeculator Mar. 21 at 7:04 PM

$GANX Nice post by Roche scientist. Novel biomarkers are going to be key to showing success in future of slowing Parkinson’s.

2 · Reply

Mateuszrozek Mar. 21 at 9:17 AM

$RYTM $GANX +100% on monday? 😏😏😏

1 · Reply

rustinpeace Mar. 21 at 2:50 AM

$GANX bring on the phase 2. between may and july is the target start pending FDA . and 111 patients in the USA. start that data rolling.

3 · Reply

SirDuncan Mar. 21 at 2:43 AM

$GANX allow me to once and for all settle this misspeak from Gene. What he really meant to say was that we are a SELL at $20. So cmon, let’s sell for $20. A billion is a nice, crisp amount.

1 · Reply

Cmoneyyyyy11 Mar. 21 at 1:26 AM

$GANX cmon Gene we are a buy @ $20

1 · Reply

AtomBull27 Mar. 20 at 10:10 PM

$GANX back in 2022/23 why did it run to $5?

1 · Reply

zampy Mar. 20 at 8:58 PM

$GANX Pinball Wizard shorting again at $1.89!!! The illustrious Tom Getty...Contra indicator!! EZZZZZZ $$$$$$$$$ HERE

0 · Reply

zampy Mar. 20 at 8:17 PM

$GANX 2s next week....I think $2.15+....Keep the faith..I like the volume 745k .....

2 · Reply

Dave2468999077844 Mar. 20 at 8:17 PM

0 · Reply

graphicswizard Mar. 20 at 8:15 PM

$GANX everyone knows that during these tumultuous times, invest in a safe asset like Gain Therapeutics stock 😝 Have a nice weekend everyone

0 · Reply

MQuick Mar. 20 at 7:46 PM

$GANX when u least expect it

0 · Reply

Jwelz90 Mar. 20 at 6:44 PM

$GANX I think some need to look at the market overall. S&P now well below the 200d. Blood in the streets everywhere. No sign of endgame for the geopolitical issues. Triple witching. Lots going on out there.

0 · Reply

Jeffreyb7173 Mar. 20 at 6:29 PM

$GANX I just don’t understand where Khalid’s buddies are… why aren’t they buying enormous amounts????

1 · Reply

microcapspeculator Mar. 20 at 5:31 PM

$GANX Big deals happen for Phase 1/2 assets. The centerpiece of Friday’s deal is Synnovation’s PI3Kα inhibitor SNV4818, an orally available drug undergoing Phase 1/2 development for breast cancer and advanced solid tumors Novartis Buys Breast Cancer Drug for $2B to Keep Up With Myriad Rivals .https://www.biospace.com/deals/novartis-buys-breast-cancer-drug-for-2b-to-keep-up-with-myriad-rivals

2 · Reply

john_Ennis Mar. 20 at 4:52 PM

$GANX Gene will have to approach monday thoughtfully. The choice of shirt and use of top 2 buttons may well set the tone. Its a buy at 1.97 its a buy at 2.06

2 · Reply

7e7en Mar. 20 at 4:47 PM

$GANX so what’s the current lay of the land? Will we be getting any hard numbers on DDC, UPDRS, etc? Are we in a holding pattern until summer to wait for dilution for supposed Phase 2 initiation? Is it pencils down until the extension data release closer to year end? What’s the status?

2 · Reply

SirDuncan Mar. 20 at 4:43 PM

$GANX At least we have something to look forward to with Monday’s fireside. I hope Gene has the strength to relay all the info in a calm, confident and approachable way.

0 · Reply

MarkeTimer Mar. 20 at 4:32 PM

$GANX please someone send a 911 to today's expiring option writers

0 · Reply

ThatDude069 Mar. 20 at 4:14 PM

$GANX big rip coming Monday. The buyers today know this

0 · Reply

hispeeddev Mar. 20 at 2:51 PM

$GANX with little fanfare, we are above 2600 watchers.

1 · Reply

timov22 Mar. 20 at 2:14 PM

$GANX Dear Gene, please take into consideration the following before the fireside chat on Monday: 1. Release the actual data numbers till day 150 including the assessed biomarkers and UPDRS scores per patient. 2. Hint about financial plans regarding Ph 2. 3. Start talking more about the addressable PD market from commercial perspective. 4. Raise investor interest by telling robust stories with data evidence and not just vague bla bla PRs. 5. Try to sound confident. 6. And stop talking about this news embargo b*llshit! Sincerely,

1 · Reply

microcapspeculator Mar. 20 at 2:01 PM

$GANX The dual impact of GBA1 in disease: from germline mutations in neurological disorderss to alterations in cancer https://www.nature.com/articles/s41420-026-03046-6

0 · Reply

Market Cap	75.00M
Revenue (ttm)	0.00
Net Income (ttm)	-20.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.07

Volume	760,600
Avg Vol	841,996
Day's Range	N/A - N/A
Shares Out	38.46M
Stochastic %K	9%
Beta	-0.03
Analysts	Strong Sell
Price Target	$7.60